Pfizer reports Phase II data for meningitis B vax
Pfizer Inc. (NYSE:PFE) reported data from a pair of Phase II trials evaluating rLP2086 to vaccinate adolescents against meningococcal disease caused by Neisseria meningitidis serogroup B. One month after the last dose in the first trial, 69-100% of subjects who received two doses and 86-99% of subjects who received three doses had human serum bactericidal antibody (hSBA) titers of >1:8 to meningococcal serogroup B strains.
The second trial found co-administration of rLP2086 diphtheria, tetanus, pertussis and inactivated polio (dTaP-IPV) vaccine Repevax did not affect immune response to Repevax. Sanofi (Euronext:SAN; NYSE:SNY) markets the dTaP-IPV vaccine. Both trials enrolled healthy volunteers aged 11-18 years. The data were presented at the European Society for Pediatric Infectious Diseases meeting in Dublin. ...